The Question of Mitigating Patient Mortality: Comparing Gilead’s ACTT-1 and the WHO’s Solidarity Trials
Update Magazine | Winter 2020
A Look Back at Risk Evaluation and Mitigation Strategies at the Food and Drug Administration in 2020: Year in Review
Update Magazine | Winter 2020
Regulations of CAR T-Cell Therapies—The Past, Present, and Future
Update Magazine | Winter 2020
Antitrust Treatment of Acceleration Provisions in Hatch-Waxman Settlements
Update Magazine | Winter 2020
Focusing on the Patient: Implementation of Key 21st Century Cures Provisions and Recommendations for the Future
Update Magazine | Winter 2020
Real World Evidence: A Potential Solution
Update Magazine | Winter 2020
Improving Cooperation Between the Nicotine Industry and the Scientific Community: The Swedish Match Science Advisory Panel Experience
Update Magazine | Winter 2020
Deconstructing the Consent Decree: A Primer and Recent Trends for FDCA Injunctions
Update Magazine | Winter 2020
That Will Leave a Mark: FDA’s Shifting Approach to Regulating the Coronavirus Testing Market Creates Confusion, Opportunities, and Enforcement Risk GalleryThat Will Leave a Mark: FDA’s Shifting Approach to Regulating the Coronavirus Testing Market Creates Confusion, Opportunities, and Enforcement Risk
That Will Leave a Mark: FDA’s Shifting Approach to Regulating the Coronavirus Testing Market Creates Confusion, Opportunities, and Enforcement Risk
Update Magazine | Winter 2020
